SloveniaAuctuCel, a Singapore-based biotechnology company, has launched AuctuPrime, a chemically defined cell culture medium designed to eliminate reliance on animal serum and human platelet supplements in cell therapy manufacturing. This development comes amid growing demand for advanced treatments, particularly in cancer care, as Singapore and Malaysia enhance their biotechnology sectors. The new medium aims to improve consistency, reduce variability between batches, and enhance supply chain resilience by using non-animal-derived components. It supports regulatory compliance and facilitates the transition of cell therapies from research to clinical application. The initiative aligns with broader efforts to standardize manufacturing processes and ensure reliable, scalable production of cell-based therapies.
Bias read (Center): The article presents a factual update on a scientific and industrial development without overt ideological framing. While the topic relates to healthcare innovation and regulation, which can have political implications, the tone and content remain neutral, focusing on technical advancements and biop
